Arcus Biosciences Shares Outstanding 2017-2021 | RCUS

Arcus Biosciences shares outstanding from 2017 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Arcus Biosciences Annual Shares Outstanding
(Millions of Shares)
2020 55
2019 44
2018 35
2017 2
2016 1
Arcus Biosciences Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 70
2021-03-31 67
2020-12-31 55
2020-09-30 65
2020-06-30 49
2020-03-31 44
2019-12-31 44
2019-09-30 44
2019-06-30 44
2019-03-31 44
2018-12-31 35
2018-09-30 43
2018-06-30 43
2018-03-31 9
2017-12-31 2
2017-09-30 2
2017-06-30 2
2017-03-31 1
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.568B $0.078B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29